DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.
EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT
PUBLICATIONS
THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.
STUDY
OFFICIAL TITLE
DISEASE
JOURNAL/
CONGRESS
YEAR
DOWNLOAD
ADELA
TPS 43 - ADELA: A Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus vs Elacestrant + Placebo in ER+/HER2– Advanced Breast Cancer Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy
Breast
MBCC 2025
2025
LUZERN
LUZERN: Phase 2 trial of niraparib and aromatase inhibitors (AI) for pretreated hormone receptor-positive/HER2-negative germline BRCA-mutated advanced breast cancer
Breast
Cancers
2025
WIN-B
Phase IB/II study to evaluate safety and preliminary efficacy of the WEE1 inhibitor DEBIO 0123 in combination with sacituzumab govitecan (SG) in triple-negative or hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC): the WIN-B study
Breast
ASCO 2025
2025
Pooling DEBBRAH-Tuxedo
Results of a Patient-Level Pooled Analysis of Three Studies of Trastuzumab Deruxtecan in HER2-Positive Breast Cancer with Active Brain Metastases
BREAST
ESMO Open
2025
ORPHEUS
Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study
PENILE
(Journal) European Urology Oncology
2024
METALLICA
Impact of time to progression (TTP) on CDK4/6 inhibitor (CDK4/6i) therapy on progression-free survival (PFS) in HR+/HER2-/PIK3CA-mutated advanced breast cancer (ABC) patients (pts) treated with alpelisib plus endocrine therapy (ALP+ET): An exploratory analysis of the METALLICA trial
BREAST
ESMO Breast
2024
PHERGAIN
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathologic complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomized, open-label, phase 2 trial
BREAST
(Journal) The Lancet
2024
PHERGain (Substudy)
HER2DX Genomic Assay in HER2-positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from PHERGain Phase II Trial
BREAST
(Journal) Clinical Cancer Research
2024
TUXEDO-3
Patritumab deruxtecan (HER3-DXd) in active brain metastases from metastatic breast and non-small cell lung cancers, and leptomeningeal disease from advanced solid tumors: The TUXEDO-3 phase II trial.
BREAST
ASCO
2024
METALLICA
Preventing alpelisib-related hyperglycaemia in HR+/HER2-/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial
BREAST
(Journal) eClinicalMedicine
2024
LUZERN
LUZERN: Phase 2 trial of niraparib and aromatase inhibitors (AI) for pretreated hormone receptor-positive/HER2-negative germline BRCA-mutated advanced breast cancer
BREAST
ESMO Breast
2024
TRANSFAL
Prospective evaluation of predictive biomarkers for palbociclib and endocrine therapy benefit in hormone receptor (HR)-positive [+]/human epidermal growth factor receptor 2 (HER2)-negative [-] advanced breat cancer patients from PARSIFAL clinical trial: the transFAL sub-study
BREAST
AACR
2024
Other MEDSIR related articles
